Please assess the completion status of the following clinical trial:

Trial Title: Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age at least 18 years or greater~* Symptomatic low ejection fraction heart failure (weak heart muscle)~* Receiving any dose of a beta blocker for the treatment of HF (unless not able to tolerate)~* Kidney function not more than mild or moderately impaired~* High blood potassium (\>5.0 mEq/L) currently while receiving medications for heart failure OR normal blood potassium currently but previously had high potassium in the12 months prior to screening which caused a permanent reduction or discontinuation of heart failure medications~* Hospitalization for heart failure or treatment in an out patient setting with intravenous medications within the last 12 months before screening.~Exclusion Criteria:~* Current acute decompensated HF, within 4 weeks before screening. Subjects with a discharge from a hospitalization for acute decompensation of HF longer than 4 weeks before screening may be included~* Significant primary aortic or mitral valvular heart disease (except secondary mitral regurgitation due to left ventricular dilatation)~* Heart transplantation or planned heart transplantation (i.e., currently on a heart transplant waiting list) during the study period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1: Patiromer (Type: EXPERIMENTAL): Subjects will be randomized to receive a daily dose of patiromer with possible dose adjustments based on subsequent local serum potassium levels.
- Group 2: Placebo (Type: PLACEBO_COMPARATOR): Subjects will be randomized to receive a daily dose of placebo with possible dose adjustments based on subsequent local serum potassium levels.

Based on this trial design, predict the completion outcome and termination type (if applicable).